Earnings Call · Q3 FY2024·2024-10-30

Q3 24EPS +2.86%·Rev n/aQ2 24EPS +17.24%·Rev n/aQ1 24EPS -9.52%·Rev n/aQ4 23EPS -13.51%·Rev n/a⚠ consensus missing

AVANOS MEDICAL, INC. AVNS

Scott Galovan — SVP, Strategy and Corporate Development

Gary Blackford — Chair

Michael Greiner — Interim CEO

−17.9%1d on move date−17.6% vs SPY3d−17.3%5d−12.6%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more AVNS calls or request research access.

More AVNS calls Browse calls Request research access